CSE: HAVN
OTC: HAVLF
FRA: 5NP
Get Notified
Edit Content
Main Menu
CSE: HAVN
OTC: HAVLF
FRA: 5NP

Press Releases

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it is supporting the founding of a Canadian counterpart to Heroic Hearts (“Heroic Hearts Canada”). The Company will provide support and funding to help Heroic Hearts Canada promote education and research to support Canadian veterans. Heroic Hearts is a registered 501(c)(3) non-profit organization operating in the United States that connects military veterans who are struggling with mental health issues resulting from trauma to therapy options such as psychotherapy supported by ayahuasca, psilocybin and ketamine. Heroic Hearts also provides professional counseling and support to veterans and is working to advance scientific research on the benefits of psychedelics through studies with the University of Georgia and the University of Colorado, Boulder. With support and funding from Havn Life, Heroic Hearts will set up its Canadian counterpart in 2021, with the goal of obtaining charitable status in Canada. Heroic Hearts Canada will serve Canadian veterans through education and advocacy for increased access to psychedelic treatment options. Heroic Hearts Canada will also develop an observational study to explore the effects of psilocybin mushrooms on post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). The observational study is planned to begin in the summer of 2021 and will take place in a jurisdiction where psilocybin is not a controlled substance. In December of 2020, Havn Life announced it would supply psychedelic compounds for an observational study run by Heroic Hearts in a jurisdiction where psilocybin is not a controlled substance. The observational study will investigate effects of psilocybin mushrooms on veterans suffering from PTSD, TBI and other mental health issues that are common among veterans. This research may help develop formulations that will be used in clinical trials to assess use of these compounds in recovery from PTSD, TBI and other trauma-related mental health conditions. Two-thirds of Canadian military personnel with PTSD do not respond completely to the best available evidence-based therapies, according to a 2018 study that examined recovery, rehabilitation and reintegration of injured service members and veterans. Further, suicide risk is higher in Canadian Armed Forces (CAF) veterans than the Canadian general population, found a "Life After Service" study published in 2016. “Our continued collaboration with Heroic Hearts has the potential to make an extraordinary impact on the mental health and overall wellbeing of military veterans,” said Tim Laidler, Havn Life Director. “As a veteran working in the mental health field, I understand the challenge of managing day-to-day activities and mental health when returning to civilian life. I am hopeful for better outcomes for veterans managing PTSD and Havn Life is looking forward to working closely with veterans and others with military backgrounds.” “I am excited to live in a time where effective mental health options are finally on the horizon for the veteran community. Heroic Hearts Project is confident that psychedelics will lead this next revolution of care. We are happy to be working with great organizations like Havn Life to make this a reality. ” said Jesse Gould, CEO of Heroic Hearts Project. Havn Life encourages other organizations to support Heroic Hearts and Heroic Hearts Canada. Future donations going to Heroic Hearts Canada will directly fund education and research to support Canadian veterans. Visit Heroic Hearts Project for more information and to donate to Heroic Hearts. Futhermore, Havn Life announces the departure of Executive Vice President of Research & Development, Susan Chapelle. The Company thanks Miss. Chapelle for her service and wishes her luck in future endeavors

Havn Life to support Canadian counterpart of Veterans’ organization Heroic Hearts

Leave a Comment / Press Releases / By

Havn Life to grow its partnership with the US-based veterans’ organization by funding and supporting the launch of its Canadian counterpart. Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, …

Havn Life to support Canadian counterpart of Veterans’ organization Heroic Hearts Read More »

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

Leave a Comment / Press Releases / By

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that, further to its news release dated December 15, 2020, the Company has completed its previously announced bought deal …

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing Read More »

Havn Life Sciences authorized product listing with Canadian health & wellness retailer, Nesters Market

Havn Life Sciences and Nesters Market, a leading Canadian retailer of Natural Health and Wellness Products, announce an authorized products listing

Leave a Comment / Press Releases / By

Nesters Market retail chain, will list and promote the full range of Havn Life’s natural health supplements across its stores in British Columbia in Q1 2021. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development …

Havn Life Sciences and Nesters Market, a leading Canadian retailer of Natural Health and Wellness Products, announce an authorized products listing Read More »

Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing

Leave a Comment / Press Releases / By

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES December 18, 2020 – Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce, further to its previously announced offering (the “Offering”) on December 15, 2020, that it has …

Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing Read More »

Havn Life provides update on retail strategy and product development

Havn Life Sciences provides update on retail strategy and product development

Leave a Comment / Press Releases / By

Havn Retail is on track for its Q1 2021 launch of its initial line of natural health supplements. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development of a full range of natural healthcare products, …

Havn Life Sciences provides update on retail strategy and product development Read More »

CBDV Exemption 56 Havn Life

Havn Life Sciences hits major milestone with research partner, Complex Biotech Discovery Ventures

Leave a Comment / Press Releases / By

Havn Research signs contract with CBDV, located at The University of British Columbia’s Vancouver campus, to begin Health Canada approved research to analyze psilocybin under Havn Life’s Section 56 exemption. The results of the analysis will allow Havn Life to begin the development of a library of psilocybin compounds. Vancouver, BC – Havn Life Sciences …

Havn Life Sciences hits major milestone with research partner, Complex Biotech Discovery Ventures Read More »

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million

Leave a Comment / Press Releases / By

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital has now agreed to buy, on a bought deal basis, 9,346,000 units (“Units”) at a price of …

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million Read More »

Havn Life Sciences announces $5 million Bought Deal Financing

Havn Life Sciences announces $5 million Bought Deal Financing

Leave a Comment / Press Releases / By

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which Eight Capital has agreed to buy, …

Havn Life Sciences announces $5 million Bought Deal Financing Read More »

Havn Life Sciences undertakes one of the first preclinical studies on psilocybin and the immune system

Leave a Comment / Press Releases / By

This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or …

Havn Life Sciences undertakes one of the first preclinical studies on psilocybin and the immune system Read More »

Havn Life Psychedelics Heroic Hearts

Havn Life Sciences to supply psychedelic compounds to clinical studies focused on veterans and PTSD

Leave a Comment / Press Releases / By

Havn Life will collaborate on future clinical studies in the U.S. and Canada with Heroic Hearts to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD). Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a Canadian biotechnology company pursuing standardized extraction …

Havn Life Sciences to supply psychedelic compounds to clinical studies focused on veterans and PTSD Read More »